Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC

Speciality: Oncology

Description:

Dr. Sushant Mittal, along with esteemed panelists Dr. Randeep Singh and Dr. Tarachand Gupta, recently led a compelling discussion on the evolving landscape of ALK-positive non-small cell lung cancer (NSCLC). The session brought together clinical insights, real-world challenges, and future directions in managing this molecular subset of lung cancer. With years of experience in thoracic oncology and precision medicine, the panel underscored the importance of multidisciplinary collaboration in improving outcomes for patients with ALK-positive NSCLC.

ALK-positive NSCLC has seen transformative progress with the advent of targeted therapies, yet significant unmet needs persist. Resistance to ALK inhibitors, particularly in later lines of treatment, continues to limit long-term efficacy. Brain metastases remain a major clinical challenge, highlighting the need for agents with better central nervous system (CNS) penetration. The panel emphasized the role of advanced diagnostics, including molecular profiling and liquid biopsy, in guiding therapy selection and detecting resistance mutations. Discussions also explored the potential of next-generation ALK inhibitors, sequencing strategies, and the integration of immunotherapy in select patient subsets. Personalized care, improved access to clinical trials, and incorporation of real-world data were spotlighted as key to bridging existing gaps.

Thank you for joining us for this important conversation on ALK-positive NSCLC. We extend our gratitude to Dr. Sushant Mittal, Dr. Randeep Singh, and Dr. Tarachand Gupta for their expertise and valuable perspectives. Stay tuned for more expert-led sessions as we continue to explore the latest advancements and address critical challenges in oncology. For continued updates and insights, keep watching this space!

See More Webinars @ Hidoc Webinars